+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Prognostic value of endocrine treatment-related symptoms in patients with breast cancer: a meta-analysis



Prognostic value of endocrine treatment-related symptoms in patients with breast cancer: a meta-analysis



Breast Cancer Research and Treatment 160(2): 197-209



Endocrine therapy is associated with improved disease-free survival (DFS) in hormone receptor-positive breast cancer, but it is also associated with many adverse events. The aim of this study was to clarify the association between endocrine treatment-related symptoms and treatment efficacy in patients receiving adjuvant endocrine therapy. EMBASE, Web of Science, PubMed, and CENTRAL databases were searched for studies that compared treatment efficacy between patients in whom adverse events did and did not occur during hormone therapy. Hazard ratios (HRs) and associated 95 % confidence intervals (CIs) for DFS and overall survival were estimated and pooled using random-effects models. Of 4665 citations identified, ten studies incorporating 32,192 patients were included in the meta-analysis. The presence of endocrine treatment-related symptoms was associated with improved DFS (HR 0.76; 95 % CI 0.68-0.85). Similar results were observed in patients with vasomotor symptoms (HR 0.76; 95 % CI 0.66-0.87) or musculoskeletal symptoms (HR 0.75; 95 % CI 0.60-0.94), in patients taking an aromatase inhibitor (HR 0.69; 95 % CI 0.57-0.85) or tamoxifen (HR 0.74; 95 % CI 0.60-0.93), and in patients with symptoms at 3-month (HR 0.74; 95 % CI 0.66-0.83), 6-month (HR 0.80; 95 % CI 0.66-0.96), or 12-month follow-up visits (HR 0.75; 95 % CI 0.68-0.83). However, no significant difference in overall survival was observed between patients with or without endocrine treatment-related symptoms (HR 0.82; 95 % CI 0.60-1.11). Sensitivity analysis excluding studies with heterogeneous factors yielded consistent results. No evidence of publication bias was observed. In our meta-analysis, endocrine treatment-related symptoms were shown to correlate with superior DFS and may therefore be useful in predicting treatment efficacy in patients with breast cancer receiving hormone therapy.

(PDF emailed within 0-6 h: $19.90)

Accession: 058637745

Download citation: RISBibTeXText

PMID: 27663434

DOI: 10.1007/s10549-016-3995-5


Related references

Endocrine Treatment-Related Symptoms and Patient Outcomes in Breast Cancer: A Meta-Analysis. Journal of Breast Cancer 21(1): 37-44, 2018

Everolimus plus endocrine vs endocrine therapy in treatment advanced ER+, HER2- breast cancer patients: A meta-analysis. Current Problems in Cancer 2018, 2018

Effectiveness of telephone-based interventions on health-related quality of life and prognostic outcomes in breast cancer patients and survivors-A meta-analysis. European Journal of Cancer Care 27(1), 2017

Tamoxifen-related endocrine symptoms in early breast cancer patients are relieved when it is switched to anastrozole. Journal of Clinical Oncology 24(18_suppl): 10597-10597, 2016

Analysis of clinical symptoms and prognostic factors in breast cancer-related meningeal metastases. European Journal of Cancer 38(Supplement 3): S70-S71, 2002

A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clinical Cancer Research 11(13): 4741-4748, 2005

Endocrine therapy alone vs. chemotherapy plus endocrine therapies for the treatment of elderly patients with endocrine-responsive and node positive breast cancer: a retrospective analysis of a multicenter study (Anatolian Society of Medical Oncology). Journal of B.U.On. 18(1): 64-69, 2013

microRNA-210 as a prognostic factor in patients with breast cancer: meta-analysis. Cancer Biomarkers 13(6): 471-481, 2015

Prognostic value of survivin expression in breast cancer patients: a meta-analysis. Tumour Biology 34(4): 2053-2062, 2013

Prognostic Value of β-catenin Expression in Breast Cancer Patients: a Meta-analysis. Asian Pacific Journal of Cancer Prevention 16(14): 5625-5633, 2016

Effects of Acupuncture on Menopause-Related Symptoms in Breast Cancer Survivors: A Meta-analysis of Randomized Controlled Trials. Cancer Nursing 39(3): 228-237, 2017

Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with breast cancer treated with HER2 blockade. Breast 24(6): 699-704, 2016

Prognostic value of matrix metalloproteinase 9 expression in breast cancer patients: a meta-analysis. Asian Pacific Journal of Cancer Prevention 14(3): 1615-1621, 2014

Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients. Breast Cancer Research and Treatment 153(3): 477-491, 2016

Prognostic value of stromal decorin expression in patients with breast cancer: a meta-analysis. Journal of Thoracic Disease 7(11): 1939-1950, 2015